Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04256018 · ClinicalTrials.gov registry record · Phase 2
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
A Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04256018: Recruiting Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Stanford University.
NCT04256018 is a Phase 2 study of Mycosis Fungoides and Sezary Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04256018, a Phase 2 study of Mycosis Fungoides and Sezary Syndrome, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF and SS.
Primary Outcome
Response to treatment will be assessed as the number and proportion of participants who achieve either a complete response (CR) or partial response (PR). The outcome is reported as numbers without dispersion. Clinical response will be assessed as follows. * CR: Complete disappearance of all clinical evidence of disease * PR: Decrease in size or amount of measurable disease lesions * Progressive disease (PD): Worsening of lesions; appearance of new lesions; or recurrence of lesions * Stable dise
Conditions Studied
Interventions
- DRUG Mogamulizumab
- RADIATION LD TSEBT
Study Locations (1)
California
- Stanford Cancer Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-03-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT04256018 shows while recruiting
NCT04256018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 2 interventions - of which Mogamulizumab is the first listed.
NCT04256018 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04256018 about?
NCT04256018 is a clinical study titled "Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome". The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF...
What is the current status of trial NCT04256018?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-03-30. Estimated completion is 2026-12.
What conditions does trial NCT04256018 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome.
What interventions are being tested in trial NCT04256018?
The interventions under investigation include: Mogamulizumab (DRUG), LD TSEBT (RADIATION).
Who is sponsoring clinical trial NCT04256018?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04256018 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04256018's enrollment target sits among peer trials
30 12th of 19 higher than 7 of 19 other Mycosis Fungoides trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mycosis Fungoides trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI